Alexandra D Carides
Overview
Explore the profile of Alexandra D Carides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aapro M, Schmoll H, Jahn F, Carides A, Webb R
Cancer Treat Rev
. 2012 Oct;
39(1):113-7.
PMID: 23062719
Chemotherapy regimens differ according to the tumor type being treated and are associated with varying degrees of emetogenic potential. Since the distribution of risk factors for chemotherapy-induced nausea and vomiting...
2.
Hesketh P, Warr D, Street J, Carides A
Support Care Cancer
. 2010 Jul;
19(9):1297-302.
PMID: 20623144
Background: Cisplatin-based highly emetogenic chemotherapy (HEC) displays a biphasic pattern of emesis with both an early and delayed period. In contrast, moderately emetogenic chemotherapy (MEC) has a monophasic pattern. The...
3.
Warr D, Street J, Carides A
Support Care Cancer
. 2010 May;
19(6):807-13.
PMID: 20461438
Goals Of Work: A number of prognostic factors have been identified as risk factors for chemotherapy-induced emesis. This post-hoc analysis addressed whether: (1) these prognostic factors can identify a low-risk...
4.
Hesketh P, Aapro M, Street J, Carides A
Support Care Cancer
. 2009 Sep;
18(9):1171-7.
PMID: 19756774
Goals Of Work: Certain patient and treatment characteristics are predictive of chemotherapy-induced nausea and vomiting (CINV). Objectives of this analysis were: (1) confirm the importance of several previously reported adverse...
5.
Kaplan S, Roehrborn C, Meehan A, Liu K, Carides A, Binkowitz B, et al.
Urology
. 2009 Mar;
73(5):935-9.
PMID: 19328538
Objectives: To determine the effect of finasteride relative to placebo on prostate cancer (PCa) risk at each individual Gleason score in the Prostate Cancer Prevention Trial using a post hoc...
6.
Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, et al.
Pediatr Blood Cancer
. 2008 Nov;
52(2):242-7.
PMID: 18985740
Background: The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed...
7.
Cohen Y, Liu K, Heyden N, Carides A, Anderson K, Daifotis A, et al.
J Natl Cancer Inst
. 2007 Sep;
99(18):1366-74.
PMID: 17848668
Background: The Prostate Cancer Prevention Trial (PCPT) demonstrated a 24.8% reduction in the 7-year prevalence of prostate cancer among patients treated with finasteride (5 mg daily) compared with that among...
8.
Diemunsch P, Apfel C, Gan T, Candiotti K, Philip B, Chelly J, et al.
Curr Med Res Opin
. 2007 Sep;
23(10):2559-65.
PMID: 17845742
Objective: Compared with the 5HT(3) antagonist ondansetron, the NK(1) antagonist aprepitant has been shown in two double-blind trials to provide greater protection against postoperative vomiting and comparable or greater control...
9.
Gan T, Apfel C, Kovac A, Philip B, Singla N, Minkowitz H, et al.
Anesth Analg
. 2007 Apr;
104(5):1082-9, tables of contents.
PMID: 17456656
Background: Antiemetics currently in use are not totally effective. Neurokinin-1 receptor antagonists are a new class of antiemetic that have shown promise for chemotherapy-induced nausea and vomiting. This is the...
10.
Gralla R, de Wit R, Herrstedt J, Carides A, Ianus J, Guoguang-Ma J, et al.
Cancer
. 2005 Jun;
104(4):864-8.
PMID: 15973669
Background: The tendency of chemotherapeutic regimens to cause vomiting is dependent on the individual drugs in the regimen. The authors analyzed data combined from 2 Phase III trials to assess...